Shervin Harandi
Interventional Pain Medicine · Houston, TXNPI 1063771509
Payments from drug & device makers
Across 432 payments — averaging $90.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$33K
- Medtronic$1K
- AbbVie$1K
- Pacira Therapeutics, Inc.$511
- Tersera Therapeutics LLC$315
- Globus Medical$209
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,6884%
- Speaking & faculty fees$24,75563%
- Travel & lodging$2,1395%
- Food & beverage$9,92725%
- Education$6902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 160 | $33,451 |
| Medtronic(3 entities) | 30 | $1,266 |
| AbbVie(2 entities) | 68 | $1,128 |
| Pacira Therapeutics, Inc. | 29 | $511 |
| Tersera Therapeutics LLC | 16 | $315 |
| Globus Medical | 8 | $209 |
| Biodelivery Sciences International, Inc. | 13 | $199 |
| Boston Scientific | 8 | $179 |
| Collegium Pharmaceutical, Inc. | 11 | $178 |
| Scilex Pharmaceuticals Inc. | 11 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $154 |
| Amgen(2 entities) | 9 | $137 |
| Abbott | 2 | $136 |
| Lilly USA, LLC | 6 | $114 |
| Painteq LLC | 3 | $103 |
| Relievant Medsystems, Inc. | 1 | $98 |
| GRT US Holding, Inc. | 4 | $92 |
| Biohaven Pharmaceuticals, Inc. | 5 | $86 |
| Novartis | 5 | $86 |
| Assertio Therapeutics, Inc. | 5 | $65 |
| Pfizer | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Vertos Medical, Inc. | 2 | $53 |
| Eisai Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Zyla Life Sciences, Inc. | 1 | $22 |
| Innovation Technologies Inc | 1 | $22 |
| Bausch Health US, LLC | 1 | $20 |
| Vertiflex, Inc. | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Si-bone, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$23,641
- Omnia$7,285
- AUTOFILL$268
- KYPHON Balloon Kyphoplasty$185
- SYNCHROMED$179
- INTELLIS ADAPTIVESTIM$162
How this compares
$39,198 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 33 | $23,741 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 633 | $16,603 |
| DayvigoLemborexant | 21 | $9,867 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 97 | $6,224 |
| Lidocaine | 58 | $4,746 |
| Gabapentin | 219 | $3,621 |
| Buprenorphine | 12 | $2,658 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 101 | $2,430 |
| Tramadol Hcl | 220 | $2,012 |
| Pregabalin | 64 | $1,298 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $1,086 |
| Tizanidine Hcl | 144 | $976 |
| Oxycodone Hcl | 30 | $841 |
| Diclofenac Sodium | 22 | $724 |
| Baclofen | 47 | $506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $178 | $23,74133 claims |
| Eisai Inc.Dayvigo | $53 | $9,86721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Houston
- Ioannis SkaribasHouston$979K
- Brian BruelHouston$219K
- George AtallahHouston$48K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.